María J. Costa

A post-hoc subgroup analysis of data from a six month clinical trial comparing the efficacy and safety of losmapimod in moderate-severe COPD patients with ≤2% and >2% blood eosinophils

Joanna Marks-Kończalik, María J. Costa, Jon Robertson et al. · Respiratory Medicine · 2015 · 30 citations · Full text

Month Clinical Trial, Advanced Lung Disease, Moderate-severe Copd Patients +5

Serine leucocyte proteinase inhibitor-treated monocyte inhibits human CD4+ lymphocyte proliferation

Diego Guerrieri, Nancy Liliana Tateosian, Paulo C. Maffía et al. · Immunology · 2011 · 26 citations · Full text

Adaptive Immune Response, Immunology, Immune Regulation +17

Biological effects of p38 MAPK inhibitor losmapimod does not translate to clinical benefits in COPD

Steven Pascoe, María J. Costa, Joanna Marks-Kończalik et al. · Respiratory Medicine · 2017 · 21 citations

Biological Effects, Advanced Lung Disease, Medicine +6

Inflammatory mediators in exhaled breath condensate of healthy donors and exacerbated COPD patients

Nancy Liliana Tateosian, María J. Costa, Diego Guerrieri et al. · Cytokine · 2012 · 20 citations

Inflammation, Lung Deposition, Allergy +11

Anti‐tumor effect of SLPI on mammary but not colon tumor growth

Nicolás Oscar Amiano, María J. Costa, R. Macarena Reiteri et al. · Journal of Cellular Physiology · 2012 · 10 citations · Full text

Immunology, Colon Tumor Growth, Pathology +19